
Eli Lilly has taken a $30 million hit after abandoning late-stage development of its investigational cancer drug enzastaurin. The compound …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

